TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

NCT04817826 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Microsatellite Instability

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Gruppo Oncologico del Nord-Ovest